Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | OTC | P00480 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | NPY4R | P50391 | 4/20 | 0.34 |
| ▸ | NPY1R | P25929 | 3/20 | 0.34 |
| ▸ | NPY2R | P49146 | 2/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | CPB1 | P15086 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.33 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.32 |
| ▸ | TUBB | P07437 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL693611 | 1.00 | GSR (0.42) | GSRMMP2OTCITGB3ITGA2B | |
| Arginine SCHEMBL28491547 | 1.00 | GSR (0.42) | GSRMMP2OTCITGB3ITGA2B | |
| Arginine SCHEMBL29263954 | 1.00 | GSR (0.42) | GSRMMP2OTCITGB3ITGA2B | |
| Arginine SCHEMBL1063567 | 1.00 | GSR (0.42) | GSRMMP2OTCITGB3ITGA2B | |
| Arginine SCHEMBL15525634 | 0.99 | GSR (0.41) | GSRMMP2OTCITGB3ITGA2B | |
| Arginine SCHEMBL20918548 | 0.96 | GSR (0.39) | GSRMMP2OTCITGB3ITGA2B | |
| Arginine SCHEMBL2337389 | 0.96 | GSR (0.39) | GSRMMP2OTCITGB3ITGA2B | |
| Arginine SCHEMBL25294109 | 0.95 | GSR (0.38) | GSRMMP2OTCITGB3ITGA2B | |
| Arginine SCHEMBL8314691 | 0.95 | GSR (0.38) | GSRMMP2OTCITGB3ITGA2B | |
| Arginine SCHEMBL1537331 | 0.95 | OTC (0.38) | OTCNPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2753691-B1 | NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF | INST NAT SANTE RECH MED (FR) | 2020-07-22 | — | — | EP | claimed |
| US-9249406-B2 | Mutated tissue plasminogen activators and uses thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2016-02-02 | — | — | US | claimed |
| US-20150050264-A2 | NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2015-02-19 | — | — | US | claimed |
| US-20140212406-A1 | NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2014-07-31 | — | — | US | claimed |
| WO-2013034710-A1 | NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2013-03-14 | — | — | WO | claimed |
| US-20230391869-A1 | INHIBITION OF PLATELET AGGREGATION USING ANTI-HUMAN GPVI ANTIBODIES | Université de Paris (FR) | 2023-12-07 | — | — | US | disclosed |
| WO-2023156683-A1 | TREATMENT OF CARDIOVASCULAR DISEASES USING ANTI-HUMAN GPVI ANTIBODIES | ACTICOR BIOTECH (FR) | 2023-08-24 | — | — | WO | disclosed |
| US-11692033-B2 | Inhibition of platelet aggregation using anti-human GPVI antibodies | ACTICOR BIOTECH (FR) | 2023-07-04 | — | — | US | disclosed |
| US-11220680-B2 | Polypeptide for treating pathological blood clots | Immunwork Inc. (TW) | 2022-01-11 | — | — | US | disclosed |
| EP-3883972-A1 | POLYPEPTIDE FOR TREATING PATHOLOGICAL BLOOD CLOTS | Immunwork Inc. (TW) | 2021-09-29 | — | — | EP | disclosed |
| EP-2753691-B1 | NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF | INST NAT SANTE RECH MED (FR) | 2020-07-22 | — | — | EP | disclosed |
| US-20200157519-A1 | POLYPEPTIDE FOR TREATING PATHOLOGICAL BLOOD CLOTS | Immunwork Inc. (TW) | 2020-05-21 | — | — | US | disclosed |
| US-20170056517-A1 | Multi-arm linker constructs for treating pathological blood clots | Immunwork Inc. (TW) | 2017-03-02 | — | — | US | disclosed |
| US-20170056518-A1 | Pharmaceuticals in joint-linker configurations for treating pathological blood clots | Immunwork Inc. (TW) | 2017-03-02 | — | — | US | disclosed |
| US-20170056519-A1 | Fusion proteins for treating pathological blood clots | Immunwork Inc. (TW) | 2017-03-02 | — | — | US | disclosed |
| US-20160194623-A1 | NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2016-07-07 | — | — | US | disclosed |
| US-9249406-B2 | Mutated tissue plasminogen activators and uses thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2016-02-02 | — | — | US | disclosed |
| US-20150050264-A2 | NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2015-02-19 | — | — | US | disclosed |
| US-20140212406-A1 | NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2014-07-31 | — | — | US | disclosed |
| WO-2013034710-A1 | NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220680-B2 | Polypeptide for treating pathological blood clots | PLAT, PLG, FGB | GSR 3526/4885MMP2 105/4885OTC 1580/4885 |
| US-20170056518-A1 | Pharmaceuticals in joint-linker configurations for treating pathological blood clots | F2, PLAT, PFKP | GSR 2850/4885MMP2 698/4885OTC 3209/4885 |
| US-20170056519-A1 | Fusion proteins for treating pathological blood clots | F13B, FGB, PLAUR | GSR 3544/4885MMP2 1101/4885OTC 4420/4885 |
| US-20200157519-A1 | POLYPEPTIDE FOR TREATING PATHOLOGICAL BLOOD CLOTS | PLAT, PLG, FGB | GSR 3526/4885MMP2 105/4885OTC 1580/4885 |
| US-20170056517-A1 | Multi-arm linker constructs for treating pathological blood clots | FGB, PLAUR, CD47 | GSR 2547/4885MMP2 933/4885OTC 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.